Provided by Tiger Fintech (Singapore) Pte. Ltd.

BridgeBio Pharma, Inc.

49.08
-1.1500-2.29%
Post-market: 48.90-0.1800-0.37%19:32 EDT
Volume:1.49M
Turnover:73.66M
Market Cap:9.38B
PE:-11.99
High:50.73
Open:50.61
Low:48.84
Close:50.23
52wk High:51.86
52wk Low:21.72
Shares:191.17M
Float Shares:151.20M
Volume Ratio:0.69
T/O Rate:0.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.0935
EPS(LYR):-2.8793
ROE:-1789.67%
ROA:-41.96%
PB:-5.25
PE(LYR):-17.05

Loading ...

Helix Acquisition Corp. II Retains Over 60% of Trust Account Post-Redemptions, Securing $382 Million for BridgeBio Oncology Merger

Reuters
·
Aug 06

Helix Acquisition Corp. Ii Retains More Than 60% of Trust Account After Redemptions in Connection With Business Combination With BridgeBio Oncology Therapeutics

THOMSON REUTERS
·
Aug 06

BridgeBio Pharma Inc : Scotiabank Raises Target Price to $57 From $55

THOMSON REUTERS
·
Aug 06

Stock Track | BridgeBio Pharma Plunges 11.40% Pre-market Following Wider-Than-Expected Q2 Loss

Stock Track
·
Aug 06

Why Are Analysts Growing More Bullish on BridgeBio Pharma (BBIO) Ahead of Q2 2025 Earnings?

Simply Wall St.
·
Aug 06

Stock Track | BridgeBio Pharma Plunges 14% After Reporting Wider-Than-Expected Q2 Loss

Stock Track
·
Aug 06

Stock Track | BridgeBio Pharma Plunges 10% After Hours on Wider Q2 Loss Despite Revenue Beat

Stock Track
·
Aug 06

BridgeBio Pharma Shares Down in After-Hours Trading Following Results, Last Down 12% at $42.93

THOMSON REUTERS
·
Aug 06

BridgeBio Pharma Inc. Unveils Corporate Presentation Highlighting FDA Approvals and Advancements in Key Clinical Trials

Reuters
·
Aug 06

BridgeBio Pharma Reports Q2 2025 Revenue of $110.6M; Net Loss Widens to $181.9M, EPS Drops to $0.95

Reuters
·
Aug 06

BridgeBio Pharma Inc - Fortify Phase 3 Topline Results Expected Fall 2025

THOMSON REUTERS
·
Aug 06

BridgeBio Pharma Inc - Propel 3 Phase 3 Topline Results Expected Early 2026

THOMSON REUTERS
·
Aug 06

Corrected-BridgeBio Pharma Q2 Revenue USD 110.6 Million VS. Ibes Estimate USD 91.4 Million (Corrects Amount)

THOMSON REUTERS
·
Aug 06

Helix Acquisition Corp. II Conducted Extraordinary General Meeting

Reuters
·
Aug 05

Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains. -- Barrons.com

Dow Jones
·
Jul 31

Cantor Fitzgerald Remains a Buy on BridgeBio Pharma (BBIO)

TIPRANKS
·
Jul 29

BRIEF-Novel Human Genetics Evidence Confirms Estimates Of Genetic Prevalence, Underdiagnosis, And Potentially Greater Symptom Burden Of Gain-Of-Function CASR Variants Associated With ADH1

Reuters
·
Jul 23

BridgeBio Pharma Announces Full Enrollment of Phase 3 Trial for Encaleret, Aiming to Address Underdiagnosed ADH1 Disorder

Reuters
·
Jul 23

BridgeBio Pharma Inc. to Release Second Quarter 2025 Financial Results

Reuters
·
Jul 22

Truist Securities Initiates Coverage on BridgeBio Pharma With Buy Rating, $66 Price Target

MT Newswires Live
·
Jul 21